Literature DB >> 12970238

Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure.

Vasant Jayasankar1, Y Joseph Woo, Lawrence T Bish, Timothy J Pirolli, Subhasis Chatterjee, Mark F Berry, Jeffrey Burdick, Timothy J Gardner, H Lee Sweeney.   

Abstract

BACKGROUND: Despite advances in surgical and percutaneous coronary revascularization, ongoing ischemia that is not amenable to standard revascularization techniques is a major cause of morbidity and mortality. Hepatocyte Growth Factor (HGF) has potent angiogenic and anti-apoptotic activities, and this study evaluated the functional and biochemical effects of HGF gene transfer in a rat model of postinfarction heart failure. METHODS AND
RESULTS: Lewis rats underwent ligation of the left anterior descending coronary artery with direct intramyocardial injection of replication-deficient recombinant adenovirus encoding HGF (n=10) or empty null virus as control (n=9), and animals were analyzed after six weeks. Pressure-volume conductance catheter measurements demonstrated significantly preserved contractile function in the HGF group compared with Null control animals as measured by maximum developed LV pressure (79+/-5 versus 56+/-4 mm Hg, P<0.001) and maximum dP/dt (2890+/-326 versus 1622+/-159 mm Hg/sec, P<0.01). Significant preservation of LV geometry was associated with HGF treatment (LV Diameter HGF 13.1+/-0.54 versus Null 14.4+/-0.15 mm P<0.01; LV wall thickness 1.73+/-0.10 versus 1.28+/-0.07 mm P<0.01). Angiogenesis was significantly enhanced in HGF treated animals as measured by both Von Willebrand's Factor immunohistochemical staining and a microsphere assay. TUNEL analysis revealed a significant reduction in apoptosis in the HGF group (3.42+/-0.83% versus 8.36+/-1.16%, P<0.01), which correlated with increased Bcl-2 and Bcl-xL expression in the HGF animals.
CONCLUSIONS: Hepatocyte Growth Factor gene transfer following a large myocardial infarction results in significantly preserved myocardial function and geometry, and is associated with significant angiogenesis and a reduction in apoptosis. This therapy may be useful as an adjunct or alternative to standard revascularization techniques in patients with ischemic heart failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970238     DOI: 10.1161/01.cir.0000087444.53354.66

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  29 in total

1.  Administration of pigment epithelium-derived factor inhibits left ventricular remodeling and improves cardiac function in rats with acute myocardial infarction.

Authors:  Shin-ichiro Ueda; Sho-ichi Yamagishi; Takanori Matsui; Yuko Jinnouchi; Tsutomu Imaizumi
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

2.  Anti-inflammatory activities of hepatocyte growth factor in post-ischemic heart failure.

Authors:  Shu-Ling Rong; Xiao-Lin Wang; Yi-Cheng Wang; Huan Wu; Xue-Dong Zhou; Ze-Kun Wang; Yu-Chuan Wang; Cun-Shui Xue; Bao Li; Dong-Lai Gao
Journal:  Acta Pharmacol Sin       Date:  2018-05-24       Impact factor: 6.150

3.  Macrophage-specific expression of urokinase-type plasminogen activator promotes skeletal muscle regeneration.

Authors:  Margaret L Novak; Scott C Bryer; Ming Cheng; Mai-Huong Nguyen; Kevin L Conley; Andrew K Cunningham; Bing Xue; Thomas H Sisson; Jae-Sung You; Troy A Hornberger; Timothy J Koh
Journal:  J Immunol       Date:  2011-06-27       Impact factor: 5.422

Review 4.  The present and future role of ultrasound targeted microbubble destruction in preclinical studies of cardiac gene therapy.

Authors:  Lijun Qian; Barsha Thapa; Jian Hong; Yanmei Zhang; Menglin Zhu; Ming Chu; Jing Yao; Di Xu
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

5.  Preventing local regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 enhances angiogenesis.

Authors:  Gary R Small; Patrick W F Hadoke; Isam Sharif; Anna R Dover; Danielle Armour; Christopher J Kenyon; Gillian A Gray; Brian R Walker
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-10       Impact factor: 11.205

6.  Combination stem cell therapy for heart failure.

Authors:  Thomas E Ichim; Fabio Solano; Fabian Lara; Jorge Paz Rodriguez; Octav Cristea; Boris Minev; Famela Ramos; Erik J Woods; Michael P Murphy; Doru T Alexandrescu; Amit N Patel; Neil H Riordan
Journal:  Int Arch Med       Date:  2010-04-14

7.  Computational protein design to reengineer stromal cell-derived factor-1α generates an effective and translatable angiogenic polypeptide analog.

Authors:  William Hiesinger; Jose Manuel Perez-Aguilar; Pavan Atluri; Nicole A Marotta; John R Frederick; J Raymond Fitzpatrick; Ryan C McCormick; Jeffrey R Muenzer; Elaine C Yang; Rebecca D Levit; Li-Jun Yuan; John W Macarthur; Jeffery G Saven; Y Joseph Woo
Journal:  Circulation       Date:  2011-09-13       Impact factor: 29.690

8.  Bioengineering the infarcted heart by applying bio-inspired materials.

Authors:  Emil Ruvinov; Tamar Harel-Adar; Smadar Cohen
Journal:  J Cardiovasc Transl Res       Date:  2011-06-08       Impact factor: 4.132

Review 9.  Re-engineered stromal cell-derived factor-1α and the future of translatable angiogenic polypeptide design.

Authors:  William Hiesinger; Andrew B Goldstone; Y Joseph Woo
Journal:  Trends Cardiovasc Med       Date:  2012-08-16       Impact factor: 6.677

10.  Quantitative MR measurements of regional and global left ventricular function and strain after intramyocardial transfer of VM202 into infarcted swine myocardium.

Authors:  Marcus Carlsson; Nael F Osman; Philip C Ursell; Alastair J Martin; Maythem Saeed
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-06       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.